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Abstract
Background: The aim of the present study was to investigate whether a previously shown survival benefit
resulting from routine early invasive management of unselected patients with acute non-ST-segment elevation
myocardial infarction (NSTEMI) may differ according to smoking status and age.
Methods: Post-hoc analysis of a prospective observational cohort study of consecutive patients admitted for
NSTEMI in 2003 (conservative strategy cohort [CS]; n = 185) and 2006 (invasive strategy cohort [IS]; n = 200). A
strategy for transfer to a high-volume invasive center and routine early invasive management was implemented in
2005. Patients were subdivided into current smokers and non-smokers (including ex-smokers) on admission.
Results: The one-year mortality rate of smokers was reduced from 37% in the CS to 6% in the IS (p < 0.001), and
from 30% to 23% for non-smokers (p = 0.18). Non-smokers were considerably older than smokers (median age 80 vs.
63 years, p < 0.001). The percentage of smokers who underwent revascularization (angioplasty or coronary artery
bypass grafting) within 7 days increased from 9% in the CS to 53% in the IS (p < 0.001). The corresponding numbers
for non-smokers were 5% and 27% (p < 0.001). There was no interaction between strategy and age (p = 0.25), as
opposed to a significant interaction between strategy and smoking status (p = 0.024). Current smoking was an
independent predictor of one-year mortality (hazard ratio 2.61, 95% confidence interval 1.43-4.79, p = 0.002).
Conclusions: The treatment effect of an early invasive strategy in unselected patients with NSTEMI was more
pronounced among smokers than non-smokers. The benefit for smokers was not entirely explained by differences
in baseline confounders, such as their younger age.
Background
Early invasive management of non-ST-segment eleva-
tion myocardial infarction (NSTEMI) has been shown,
when contrasted with a conservative treatment
approach, to improve clinical outcome [1]. Whether
such an effect differs between smokers and non-smo-
kers is difficult to explore, since smokers with NSTEMI
are substantially younger than non-smokers. To the
best of our knowledge, such an exploration has only
been attempted in a sub-analysis of the FRISC II study
[2], where allocation to earlyi n v a s i v et r e a t m e n tf o r
non-ST-segment elevation acute coronary syndrome
(NSTE-ACS) was associated with a clinical benefit in
non-smokers only [3]. The risk level was moderate, as
reflected in a 6 months mortality rate of 2%. The favor-
able effect of early invasive management was exclusively
driven by a reduction of recurrent MI and no informa-
tion on age-differences was provided. In a study of
unselected patients with acute myocardial infarction
(AMI), we found that for NSTEMI the one-year mor-
tality rates were 32% with conservative management
and 21% with an early invasive approach [4]. The pur-
pose of the present analysis was to investigate whether
this survival benefit may differ according to smoking
status and age.
* Correspondence: erlend.aune@siv.no
1Department of Cardiology, Vestfold Hospital Trust, Toensberg, Norway
Full list of author information is available at the end of the article
Aune et al. BMC Cardiovascular Disorders 2010, 10:59
http://www.biomedcentral.com/1471-2261/10/59
© 2010 Aune et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Methods
Details on the study design and methodology are pub-
lished elsewhere [4]. In brief, all patients referred to our
non-invasive hospital during two one-year periods with
a suspected AMI were prospectively registered. The
diagnosis of AMI was made in accordance with the Eur-
opean Society of Cardiology/American College of Cardi-
ology criteria of 2000 [5]. The conservative strategy
cohort (CS) included patients admitted from February 1,
2003 through to January 31, 2004. The invasive strategy
cohort (IS) included patients admitted from February
15, 2006 through to February 14, 2007. Patients were
transferred approximately 100 km (63 miles) to the clo-
sest high-volume invasive center (Rikshospitalet Univer-
sity Hospital, Oslo, Norway).
A diagnosis of AMI was, in the case of both cohorts,
made in the presence of typical symptoms and elevated
troponin T greater than a cutoff level of ≥ 0.1 μg/L.
According to the electrocardiographic findings, AMI
was sub-classified into ST-segment elevation myocardial
infarction (STEMI) and NSTEMI. Current smokers
included those who had smoked within the last three
months. Non-smokers were defined as never-smokers
a n de x - s m o k e r sw h oh a ds t o p p e dm o r et h a nt h r e e
months prior to admission. Data on smoking cessation
was not collected due to the fact that informed consent
was required in order to undergo one-year follow-up on
morbidity and medication. This, however, could only be
obtained in 55% of the study group due to limitations
such as patient refusal, old age, dementia and geographi-
cal factors. Baseline risk evaluation for both cohorts
included the Global Registry of Acute Coronary Events
(GRACE) risk score for 6-month mortality [6]. The pri-
mary outcome was all-cause death after one year.
Patients with NSTEMI have platelet-rich thrombi, as
opposed to predominantly fibrin-rich thrombi in STEMI
[7]. We therefore felt it appropriate to evaluate sepa-
rately the impact of tobacco smoking for each type of
AMI. The present report addresses NSTEMI patients
only, since it would be underpowered to explore the
impact of smoking status in the smaller subset of
STEMI patients.
Both the regional ethics committee for South-East
Norway Regional Health Authority and the Norwegian
Social Science Data Services approved the study.
Statistical analysis
In the post-hoc analysis, Mann-Whitney U test was used
for comparison of continuous data between different
groups of patients. Proportions were analyzed by c
2 test
or Fisher’s exact test. Kaplan-Meier plots and Log rank
tests were used for unadjusted comparison of survival
between different subsets of patients, i.e. smokers and
cohort. Two multiple Cox proportional hazards
regression models were used for additional survival ana-
lyses. In model 1, explanatory variables with a p-value ≤
0.05 in the main study’s multiple regression analysis [4]
(treatment strategy, age, s-creatinine and previous left
ventricular systolic dysfunction), in addition to smoking
status at admission, as well as aspirin and statin usage
during hospitalization, were used to assess the hazard
ratio (HR) for death after one year. Interaction terms
between age/strategy and smoking/strategy were
included and tested. In model 2, GRACE risk
score (including age, heart rate, systolic blood pressure,
s-creatinine, Killip Class, cardiac arrest at admission, ST-
segment deviation and elevated cardiac markers) was used
for the adjustment of differences at baseline risk, with the
analysis presented separately for smokers and non-smo-
kers. In both models, the cohort was used as a surrogate
variable for the treatment strategy. The assumption of pro-
portional hazards was explored with partial residual plots.
Two-tailed p-values below 0.05 were considered statisti-
cally significant. The analyses were implemented using
SPSS® 16.0 (SPSS Inc, Chicago, IL).
Results
In 2003 (CS) 185 patients were admitted with NSTEMI.
Data on smoking status was obtained in 181 cases
(98%), of whom 54 (30%) were current smokers. In 2006
(IS) 200 patients were admitted with NSTEMI. Data on
smoking status was complete, with 49 (25%) patients
found to be current smokers (p = 0.29 versus CS). Base-
line characteristics according to smoking status at
admission and treatment cohort are presented in
Table 1. Smokers were significantly younger than
non-smokers both in the IS (median age 60 vs. 81 years,
p < 0.001) and the CS (median age 66 vs. 79 years, p <
0.001). Smokers in the IS had a significantly lower s-
creatinine (median [25
th-75
th percentile] 76 [69-96] vs.
95 [75-113] μmol/L, p = 0.014) compared with smokers
in the CS. More smokers in the IS had prior PCI when
compared to smokers in the CS. Otherwise, baseline risk
factors, including GRACE risk score, were similar
among smokers and non-smokers within both cohorts.
Total mortality
The Kaplan-Meier estimates of one-year survival accord-
ing to smoking status and treatment strategy are shown
in Figure 1. Smokers in the CS had a one-year mortality
of 37% (20/54) as compared with 6% (3/49) in the IS
(p < 0.001). The corresponding numbers for non-smo-
kers were 30% (38/127) and 23% (35/151) (p = 0.18).
The results from the Cox proportional hazards regres-
sion analyses are presented in Table 2 (model 1) and
Table 3 (model 2). In model 1, a statistically significant
interaction was found between strategy and smoking
(p = 0.024). Current smoking was an independent
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Page 2 of 7predictor of mortality (HR 2.61, 95% confidence interval
[CI] 1.43-4.79, p = 0.002). No interaction was observed
between strategy and age (p = 0.25). When adjusted for
GRACE risk score at admission (model 2) IS was asso-
ciated with a statistically significant reduction of one-
year mortality for smokers (HR 0.20, 95% CI 0.06-0.68,
p = 0.010), but not for non-smokers (HR 0.79, 95% CI
0.49-1.28, p = 0.34).
Invasive procedures and mortality within 7 days
Among smokers, the proportion of patients who under-
went coronary angiography within 7 days increased
from 11% in the CS to 78% in the IS. This was accom-
panied by a 6-fold increase in percutaneous coronary
intervention (PCI) and coronary artery bypass grafting
( C A B G )d u r i n gt h es a m et i m ep e r i o d( F i g u r e2 a ) .T h e
7-days mortality rate reduced from 17% in the CS to 0%
in the IS (Figure 2b).
The proportion of non-smokers who underwent cor-
onary angiography within 7 days was 6% in the CS and
49% in the IS. The corresponding data for early revascu-
larization and death are presented in Figure 3a and Fig-
ure 3b, indicating a less pronounced and non-significant
decrease in mortality as compared with smokers.
Non-smokers in the IS who had revascularization
within 7 days were significantly younger than those not
undergoing this treatment (median [25
th-75
th percentile]
age 71 [62-77] vs. 83 [74-88] years, p < 0.001). The cor-
responding figures for smokers were 58 (50-70) vs. 63
(59-78) years (p = 0.035). Similar age-differences were
observed in the CS.
Table 1 Baseline characteristics for NSTEMI patients.
Non-smokers Smokers*
CS
(n = 127)
IS
(n = 151)
p-value CS
(n = 54)
IS
(n = 49)
p-value
Age (years) 79 (72-86) 81 (69-86) 0.61 66 (56-76) 60 (55-72) 0.17
Male 74 (58%) 87 (58%) 1.00 39 (72%) 34 (69%) 0.92
Medical history
Diabetes 21 (17%) 29 (19%) 0.67 6 (11%) 6 (12%) 1.00
Previous AMI 42 (33%) 53 (35%) 0.82 14 (26%) 12 (25%) 1.00
Previous LVSD† 10 (8%) 19 (13%) 0.30 7 (13%) 3 (6%) 0.40
Hypertension 46 (36%) 45 (30%) 0.31 17 (32%) 13 (27%) 0.74
Stroke 6 (5%) 17 (11%) 0.080 6 (11%) 2 (4%) 0.34
CABG 11 (9%) 20 (13%) 0.31 5 (9%) 3 (6%) 0.82
PCI 6 (5%) 10 (7%) 0.68 3 (6%) 10 (20%) 0.049
Presenting characteristics
S-Creatinine, μmol/L‡ 95 (76-128) 90 (77-115) 0.30 95 (75-116) 76 (69-97) 0.014
GRACE risk score 140 (113-166) 139 (110-164) 0.53 112 (84-160) 108 (80-131) 0.28
Categorical data presented as n (%) and continuous data as median (25
th -75
th percentile). *Smoking within last three months. †Defined as prior left ventricular
ejection fraction < 40%. ‡Conversion factor 0.0113 for mg/dL.
AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; CS, conservative strategy cohort; GRACE, global registry of acute coronary events;
IS, invasive strategy cohort; LVSD, left ventricular systolic dysfunction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary
intervention; STEMI, ST-segment elevation myocardial infarction.
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Figure 1 One-year survival in non-ST-segment elevation
myocardial infarction (NSTEMI) patients with invasive strategy
(IS) and conservative strategy (CS).
Table 2 Hazard ratios (HR) of death in patients with
NSTEMI (n = 381) during one-year follow-up using
multiple Cox proportional hazards regression (Model 1).
HR 95% CI p-value
Invasive strategy 0.80 0.50-1.27 0.34
Age per year 1.05 1.02-1.08 < 0.001
S-creatinine per unit (μmol/L) 1.005 1.003-1.007 < 0.001
Current smoking 2.61 1.43-4.79 0.002
Previous LVSD* 1.63 0.97-2.75 0.064
Statin during hospitalization 0.46 0.29-0.71 0.001
Aspirin during hospitalization 0.57 0.35-0.90 0.017
Interaction term (current smoker/strategy) 0.22 0.06-0.82 0.024
*Defined as previous left ventricular ejection fraction < 40%.
CI, confidence interval; LVSD, left ventricular systolic dysfunction; NSTEMI,
non-ST-segment elevation myocardial infarction.
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There was no difference in the usage of drug-eluting
stents (DES) in the IS between smokers and non-smo-
kers (24% vs. 21%, respectively, p = 1.00).
Medical treatment
Data on medical treatment during hospitalization are
provided in Table 4. A non-significant tendency for
more statin usage in the IS and for more aspirin usage
among smokers than non-smokers was observed. Other-
wise, the medication prescribed was similar within the
two treatment cohorts, both for smokers and non-
smokers.
Discussion
Principal findings
The main finding of this study is that smokers with
NSTEMI benefit the most from an early invasive treat-
ment strategy, and that the treatment effect seems inde-
pendent of age. For all-cause mortality the interaction
term between current smoker and strategy was
Table 3 Hazard ratios (HR) of death in patients with
NSTEMI (n = 381) during one-year follow-up using
multiple Cox proportional hazards regression according
to smoking status (Model 2).
Non-smokers
(n = 278)
Smokers (n = 103)
HR 95%
CI
p-
value
HR 95%
CI
p-
value
Invasive strategy 0.79 0.49-
1.28
0.34 0.20 0.06-
0.68
0.010
GRACE risk score (per
point)
1.03 1.02-
1.04
<0.001 1.04 1.02-
1.05
<0.001
CI, confidence interval; GRACE, global registry of acute coronary events;
NSTEMI, non-ST-segment elevation myocardial infarction.
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Figure 2 Revascularization (a) and survival (b) during first 7
days in smokers with non-ST-segment elevation myocardial
infarction (NSTEMI).
   	 



	


	



























   	 

	





	

























Figure 3 Revascularization (a) and survival (b) during first 7
days in non-smokers with non-ST-segment elevation
myocardial infarction (NSTEMI).
Table 4 Medical treatment during index hospitalization
in NSTEMI patients.
Non-smokers Smokers
CS
(n =
127)
IS
(n =
151)
p-
value
CS
(n =
54)
IS
(n =
49)
p-
value
Aspirin 103
(81%)
124
(82%)
0.95 48
(90%)
45
(92%)
0.86
Clopidogrel 92 (72%) 118
(78%)
0.34 46
(85%)
46
(94%)
0.27
Beta-
blocker
110
(87%)
123
(82%)
0.32 46
(85%)
42
(86%)
1.00
ACE-I/ARB 53 (42%) 77 (51%) 0.16 22
(41%)
19
(39%)
1.00
Statins 74 (58%) 106
(70%)
0.051 40
(74%)
44
(90%)
0.072
Categorical data presented as n (%).
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin-II receptor
blocker; CS, conservative strategy cohort; IS, invasive strategy cohort; NSTEMI,
non-ST-segment elevation myocardial infarction.
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Page 4 of 7significant, implying that the effect of an invasive strat-
egy was significantly different between smokers and
non-smokers. In this unselected population one-year
mortality for smokers decreased from 37% in the CS to
6% in the IS. Half of the fatal events among smokers in
the CS occurred within 7 days. Such a profound reduc-
tion in early mortality could not be demonstrated
among the non-smokers, where the increased use of
early invasive management was less pronounced. In
spite of the favorable findings among smokers under-
going early invasive treatment, current smoking was still
an independent predictor of one-year mortality.
Comparisons with previous studies
Several studies and registries of patients with NSTE-
ACS have compared the outcome of smokers vs. non-
smokers in order to evaluate the possible existence of a
“smoker’sp a r a d o x ” [1,8-10]. The consensus has been
that the apparently favorable outcome among younger
smokers is eliminated when adjustments for baseline
risk factors are made in various multiple regression ana-
lyses. To the best of our knowledge, the only study that
has compared the influence of early invasive vs. a con-
servative approach in smokers vs. non-smokers with
NSTE-ACS is the FRISC II trial [2]. In contrast with our
study, a clinical benefit resulting from early invasive
treatment was observed for non-smokers but not for
smokers. It must be emphasized that the study popula-
tions were different, with a much higher mortality rate
in our observational study of unselected NSTEMI
patients. In FRISC II only 68% of the patients had ele-
vated troponin and age > 75 years was an exclusion cri-
terion. In our study, 53% of the patients were > = 75
years old. Patients treated with PCI in FRISC II were
unable to be treated with DES and only 61% had stents
in the invasive group, whilst anti-platelet therapy com-
prised of ticlopidine treatment for only 3-4 weeks after
the procedure. This is in contrast to our study, where
the majority had stents, and all had clopidogrel prior to
and 9 months after the procedure. In FRISC II, early
invasive vs. conservative treatment had no influence on
total mortality. As is reflected in the favorable influence
on mortality in our study, it seems fair to assume that
the introduction of early invasive management may have
induced a reduction in both cardiac morbidity and total
mortality.
Most studies on the prognostic impact of smoking in
acute coronary syndromes have compared younger smo-
kers with older non-smokers, and, in part, ex-smokers
[8,9,11-13]. It may be speculated that smokers and non-
smokers of similar age suffering from an AMI would
differ in terms of other risk factors as well as the com-
position of the atherosclerotic lesion rendering them
open to different treatment results.
Differences in baseline confounding factors
S m o k e r sw e r ec o n s i d e r a b l yy o u n g e ra n dm o r el i k e l yt o
undergo early revascularization than non-smokers. It
could therefore be argued that the favorable effect of an
invasive strategy in the younger subgroup of smokers
can be explained solely by this difference in age and the
lower proportion of early revascularization in non-smo-
kers. However, we found no interaction between strat-
egy and age, as opposed to a significant interaction
between strategy and smoking status at admission.
Accordingly, the survival benefit of an invasive strategy
in our study seems independent of age. This is consis-
tent with previous findings from randomized trials. In
the RITA 3 trial [14] patients assigned an early interven-
tion for NSTE-ACS had a more favorable outcome than
those with a conservative strategy, with the results con-
sistent across various subgroups, including age. In two
other large randomized studies [2,15] exploring the
effect of early invasive strategy versus a conservative
approach in NSTE-ACS there were no differences in
outcome among patients subdivided into age groups ≥
65 years and < 65 years. Based upon these considera-
tions, it seems unlikely that differences in age and the
proportion of smokers and non-smokers treated with
early invasive strategy can solely explain the favorable
results obtained among smokers undergoing early inva-
sive versus conservative management.
Another potential confounding factor is the different
concomitant medical therapy given to each cohort. It
should be emphasized that there were no changes in the
recommendations for adjunctive medical treatment from
the first to the second cohort. In spite of this, we
observed a non-significant tendency for more statin
usage among smokers in the IS than in the CS. Statin
and aspirin use during hospitalization were associated
with a lower hazard ratio for mortality (model 1), but
when included in the adjusted analysis, such treatment
had no influence on the interaction between smoking
and treatment strategy.
Strengths and limitations of the study
The present study is a post-hoc analysis of a prospective
observational cohort study including all patients with
NSTEMI admitted to our hospital. This unselected
study population is representative of Norwegian patients
with NSTEMI in general, as opposed to patients
included in randomized trials with various inclusion and
exclusion criteria. On the other hand, due to the obser-
vational and nonrandomized design, our findings may
have been influenced by unidentified confounders. In
light of the relatively modest population size, potential
differences between the groups might not be statistically
significant because of type 2 errors. Due to the same
reason it did not seem appropriate to stratify age
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follow-up, such as secondary medical prophylaxis and
smoking cessation after discharge were not available.
According to observations made in studies of smoking
cessation in patients with coronary heart disease, an
apparent affect on mortality is not seen until after 2-4
years [16-18]. In recently published data from the
OASIS 5 study of NSTE-ACS patients, smoking cessa-
tion was associated with a lower rate of reinfarctions
but had no effect on mortality after 6 months [19]. The
early mortality reduction observed in our study can
therefore not be explained by a higher percentage of
quitters in the IS than in the CS. Although smokers in
t h eI Sw e r es l i g h t l yy o u n g e r ,h a ds i g n i f i c a n t l yl o w e r
s-creatinine and more statin treatment during the index
hospitalization, the favorable mortality results were still
statistically significant after adjustment for these con-
founders. Due to regulatory limitations we were not able
to study the influence on recurrent myocardial infarc-
tions. Finally, non-smokers were due to higher age and
more co-morbidity less likely to undergo invasive treat-
ment. This could have influenced our results in some
way not accounted for.
Conclusions
Unselected smokers with NSTEMI represent a subset of
patients who receive particular clinical benefit from an
early invasive strategy. This benefit seems to be inde-
pendent of age.
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